Heatwurx (PCSA)
(Delayed Data from NSDQ)
$2.09 USD
-0.04 (-1.88%)
Updated May 10, 2024 04:00 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
PCSA 2.09 -0.04(-1.88%)
Will PCSA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PCSA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCSA
Heatwurx Inc. (PCSA) Upgraded to Buy: Here's What You Should Know
PCSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PCSA
Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Oculis Holding (OCS)
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Processa Pharmaceuticals appoints Steven Cha as SVP, clinical research
Applied Dna Sciences, OptimizeRx, SCWorx among healthcare movers